Highlights Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Delayed Hong Kong S.E. Other stock markets 03:39:12 2024-05-02 am EDT			5-day change	1st Jan Change
12.58 ^HKD	+6.97%		+30.36%	-35.29%

Apr. 29	Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	Apr. 24	CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection	Apr. 08	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	CI
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	Apr. 02	CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	Apr. 01	CI
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	Mar. 28	MT
Junshi Bio's 2023 Loss Widens, Misses Estimates	Feb. 25	MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Junshi Biosciences Proposes Share Buyback	Feb. 02	MT
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	Feb. 01	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	Feb. 01	CI
Shanghai Junshi Biosciences to Narrow Losses	Jan. 31	MT
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	Jan. 31	MT
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	Jan. 30	CI
Shanghai Junshi Biosciences Co., Ltd. Receives Letter from Coherus Notifying the Company of its Intention to Terminate the Cooperation	Jan. 10	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine	Jan. 09	CI
Junshi Biosciences Secures Supplementary Application Approval for Lung Cancer Therapy in China	Jan. 03	MT
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	Jan. 02	CI
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients	Jan. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Highlights

Filters